Results 71 to 80 of about 19,637 (185)

Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia

Lipids in Health and Disease, 2009
Background Ezetimibe (Zetia®) is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. Statin, an inhibitor of cholesterol synthesis, is the first-choice drug to reduce low-density lipoprotein ...
Aoyama Naoyoshi, Machida Yoji, Yoshida Yuki, Hatakeyama Yuko, Kosugi Rie, Tojo Taiki, Yamaoka-Tojo Minako, Masuda Takashi, Izumi Tohru   +8 more
doaj   +1 more source

The Association Between Atherogenic Index of Plasma and Type 2 Diabetes Mellitus in a Multi‐Ethnic Population of Premature Coronary Artery Disease Patients: Insights From IPAD Study

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
In patients with premature coronary artery disease, higher atherogenic index of plasma was associated with prevalent type 2 diabetes and higher fasting blood sugar. Exploratory analyses suggested possible ethnicity‐related heterogeneity, while ROC analysis showed limited discrimination, supporting cautious interpretation rather than clinical screening ...
Reza Amani‐Beni, Ghazal Ghasempour Dabaghi, Noushin Mohammadifard, Ehsan Zarepur, Bahar Darouei, Mehrdad Rabiee Rad, Fahimeh Haghighatdoost, Fatemeh Nouri, Nizal Sarrafzadegan   +8 more
wiley   +1 more source

STUDYING MOLECULAR MODELLING OF THE CHOLESTEROL ABSORPTION INHIBITOR EZETIMIBE AND EVALUATION OF ITS ANTIBACTERIAL ACTIVITY [PDF]

Bulletin of Pharmaceutical Sciences. Assiut University
As is known, ezetimibe is the only drug classified as a cholesterol absorption inhibitor, working by preventing the cholesterol transporter protein Niemann-Pick C1-Like 1 (NPC1L1) from functioning.
Manila Mohammed, Saleh Trefi, Mustapha Chehna, Yaser Bitar, Ali Ibrahim   +4 more
doaj   +1 more source

Mechanisms and Predisposing Conditions for Statin‐Induced New‐Onset Type 2 Diabetes Mellitus: A Paradox Relative to Their Pleiotropic Metabolic Effects

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
The primary function of statins is to inhibit cholesterol synthesis, which contributes to their antidiabetic effects. However, the majority of the diabetic effects of statins are due to inhibition of isoprenoid synthesis. Atorvastatin, simvastatin and rosuvastatin possess the most pronounced diabetogenic properties. In contrast, lovastatin, fluvastatin,
Ali Nosrati Andevari, Mohsen Koolivand
wiley   +1 more source

Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe

Frontiers in Pharmacology, 2014
Recent clinical research has shown that atorvastatin in combination with cholesterol absorption inhibitor ezetimibe significantly reduces LDL-C level in patients with hypercholesterolemia, showing a superior lipid-lowering efficacy compared to statin ...
Omar ePatiño-Rodríguez, Irma eTorres-Roque, Maricela eMartínez-Delgado, Abraham eEscobedo-Moratilla, José ePérez-Urizar   +4 more
doaj   +1 more source

Eating Behavior, Food Consumption Frequency, and Nutritional Status Among Undergraduate Nursing Students: A Cross‐Sectional Study

Food Science &Nutrition, Volume 14, Issue 9, September 2026.
In a cross‐sectional study of 61 undergraduate nursing students in Brazil, dietary patterns were centered on rice, beans, and bread, with limited fruit and vegetable diversity and frequent coffee consumption (72.1% daily or weekly). Despite a predominantly eutrophic BMI profile (65.0%), eating behavior (TFEQ‐21 domains: Cognitive Restraint ...
Maria Laura Lacerda Nascimento, Aline Nataly Soares Vital, Taisy Cinthia Ferro Cavalcante, Emily Pereira de Souza, Amanda Alves Marcelino da Silva   +4 more
wiley   +1 more source

Combined Effects of Ezetimibe and Phytosterols on Cholesterol Metabolism

, 2011
Background— Both ezetimibe and phytosterols inhibit cholesterol absorption. We tested the hypothesis that the combination of ezetimibe and phytosterols is more effective than ezetimibe alone in altering cholesterol metabolism.
Xiaobo Lin, Karen Steger-May, Lina Ma, Richard E. Ostlund, Michael Lefevre, Susan B. Racette, Catherine Anderson Spearie   +6 more
core   +1 more source

The ezetimibe controversy: implications for clinical practice

, 2011
Low-density lipoprotein cholesterol (LDL-C) remains the primary target of lipid-lowering therapy. Achieving LDL-C goals as outlined by the National Cholesterol Education Program Adult Treatment Panel III can be difficult with statins alone; therefore ...
Ujjaini Khanderia, Randolph E. Regal, Thomas Boyden, Melvyn Rubenfire   +3 more
core   +1 more source

Mitochondria as the Hub of Apoptosis: A Comprehensive Insight From Mitochondria to Interactions With Other Organelles

MedComm, Volume 7, Issue 9, September 2026.
Mitochondria is the hub of apoptosis in various diseases. The disruption of mitochondrial structure (including membrane rupture, cristae remodeling, and mitochondrial membrane lipid redistribution), the imbalance of mitochondrial dynamics (including fusion and fission, autophagy), the release, disruption, and mutation of mitochondria DNA, as well as ...
Rubin Tan, Jinming Zhao, Rong Wang, Yue Shi, Zaozao Chen, Yixuan Ma, Na Li, Wenqing Duan, Duo Lin, Chunxiang Zhang   +9 more
wiley   +1 more source

Serious drug-induced liver disease secondary to ezetimibe [PDF]

, 2019
Ezetimibe is the first member of a new family of lipid-lowering drugs that inhibits uptake of dietary and biliary cholesterol. It was approved by the FDA in 2002 for hypercholesterolemia alone or in combination with statins.
Girbau, Anna, Castellote Alonso, José, Ariza Cardenal, Javier, Rota Roca, Rosa, Xiol Quingles, Xavier   +4 more
core   +1 more source